RARE Stock Craters As Ultragenyx Slashes Outlook After Trial Failure

Ultragenyx Pharmaceutical Inc. faces intensified pressure as pivotal clinical trial setbacks dominate sentiment, with stocks have been trading down by -46.95 percent.

Live Update At 09:18:55 EDT: On Thursday, September 03, 2026 Ultragenyx Pharmaceutical Inc. stock [NASDAQ: RARE] is trending down by -46.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RARE, Ultragenyx Pharmaceutical Inc., just went from a slow grinder to a full-on downside momentum play. Before the news, the daily chart showed a tight range in the mid-$20s, with RARE closing at $26.53 on 2026/09/02 after several sessions between roughly $25 and $27. That’s classic consolidation. Then the Phase 3 failure hit and the stock gapped down violently, with after-hours trading printing around $14.50 — roughly a 45% haircut.

Under the hood, RARE is a classic high-burn biotech. The latest quarter shows $214M in revenue and $180M in gross profit on fat 87.8% gross margins, but the company still posted a net loss of about $92M and EBITDA of -$91M. Operating cash flow was -$97M, and RARE ended the quarter with $140M in cash and $292M in cash plus short-term investments.

That means the balance sheet can fund operations near term, but the negative -79.2% EBIT margin and -42.96% return on assets scream “cash drain.” For traders, those numbers matter now that a major pipeline driver just broke.

Why Traders Are Watching RARE After The Angelman Blowup

The RARE story turned on a single data readout. Ultragenyx’s Phase 3 Aspire trial of apazunersen, also called GTX-102, in Angelman syndrome failed both its primary cognitive endpoint and the key secondary MDRI endpoint. For a rare-disease name like RARE, this was not just another trial — this was a flagship asset. When the readout hit, the market repriced the whole story in one shot.

RARE plunged about 45% in after-hours trading, landing near $14.50. That kind of move tells you how central the program was to future revenue expectations. Active traders live for this type of volatility, but you have to respect the downside risk. The intraday tape shows heavy activity in the mid-teens with price whips inside a relatively tight band, exactly what you expect as shorts lock in gains and bottom-fishers nibble.

Management’s response is just as important as the chart. Ultragenyx said it will conduct a strategic review of apazunersen — including whether to keep funding it at all — and plans “significant expense reductions.” At the same time, the company is trying to pivot the RARE narrative back to its growing commercial portfolio, including products like GENGLYCOS and potential UX111 approval, while reaffirming a 2027 profitability target.

Wall Street, however, is not giving RARE the benefit of the doubt. William Blair cut RARE to Market Perform, warning that the failed Phase 3 raises questions about the related Aurora study of GTX-102 and shrinks near-term catalysts. Evercore ISI followed, downgrading RARE to In Line and chopping its price target to $16 from $34, and spotlighting the heavy expense load, future Crysvita loss of exclusivity, and RARE’s dependence on first‑generation AAV gene therapies in small commercial markets.

For short-term traders, that combination — broken thesis, forced cost discipline, and analyst downgrades — is exactly what fuels repeated fade-and-fail intraday setups and dead-cat bounce attempts.

Conclusion

For RARE, the failed Angelman Phase 3 trial is more than a bad headline; it’s a reset of the whole pipeline story. Ultragenyx now has to lean harder on its commercial rare-disease drugs and near-term launches while cutting expenses and deciding whether to keep funding apazunersen at all. That decision is the overhang: continue burning cash on a damaged asset, or kill it and show discipline to the market.

Fundamentally, RARE still has real revenue and very high gross margins, but the company is deeply unprofitable with negative equity and heavy quarterly cash burn. When you overlay that with a 45% price collapse and back-to-back downgrades, you get a name that will likely trade more on emotion, headlines, and order flow than on spreadsheets for a while.

For momentum traders, RARE is now on the watchlist as a classic “broken biotech” — big gap down, clear catalyst, and a CEO scrambling to defend a 2027 profitability goal. The key is to stay disciplined. In Tim Sykes’ words, “The market doesn’t care about your opinion, only your risk management.” As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.”. This RARE move is a live case study in that mindset: study the chart, understand the news, and always let risk control every trade.

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks